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EDITORIAL 
Adenosine-Based Modulation of Brain Activity 
  The purine ribonucleoside adenosine is an endogenous modulator of brain function uniquely positioned 
to integrate a wide variety of signalling pathways. Due to its early evolutionary roots – adenosine was 
already part of the “RNA-world” and strategically placed to bridge cellular activities (as building block of 
nucleic acids) with energy supplies (adenosine-5’-triphosphate, ATP) – it is not surprising that adenosine 
has evolved into a “master regulator” with important functions in every known form of life and in almost 
every organ system studied. This Hot Topics Issue is devoted to the role of adenosine as regulator of brain 
activity  in  health  and  disease.  Due  to  the  advent  of  modern  molecular  tools,  the  adenosine-field  has 
experienced a revival during the past decade that led to the development of experimental adenosine-based 
therapeutics. Therapeutic modulation of the adenosine system holds much promise for the soft therapy of 
a wide variety of neurological or neuropsychiatric conditions. However, the ubiquitous distribution of 
components of the adenosine-based regulatory system constitutes a therapeutic challenge that needs to be 
met by specificity. 
  Bruno Frenguelli and Nicholas Dale provide an introduction to the topic and discuss the potential 
sources  of  adenosine  and  ATP,  and  mechanisms  of  their  release  into  the  extracellular  space.  With 
microelectrode biosensors that are specific for the online detection of adenosine or ATP in vitro or in vivo 
the authors have developed and used an innovative tool to study changes in ambient adenosine as  a 
consequence of ischemia and epilepsy in real time. Ana Sebastiao and Alexandre Ribeiro discuss the 
downstream pathways of adenosine and how adenosine can tune and fine-tune the activity of a wide 
spectrum of neurotransmitters and neuromodulators. A high degree of complexity becomes possible via 
receptor-receptor interactions and crosstalk between adenosine receptors and transporters. While the first 
two chapters focus on molecular mechanisms, with an emphasize on upstream and downstream pathways, 
respectively,  the  remaining  review  articles  are  devoted  to  the  role  of  adenosine  regulation  and 
dysregulation within the context of specific physiological and pathophysiological conditions. Hai-Ying 
Shen and Jiang-Fan Chen present novel psychopharmacological findings that highlight the unique role 
of the adenosine A2A receptor as a key player for neuropsychiatric conditions including addiction, mood-
control,  cognitive  function,  and  schizophrenia.  The  molecular  basis  for  these  interactions  has  been 
elaborated in transgenic mice with brain-region specific deletions of the A2A receptor (e.g. striatum versus 
forebrain); in particular, the A2A receptor emerges as a crucial upstream regulator of both glutamatergic 
and dopaminergic neurotransmission. Anisur Rahman highlights current knowledge on the role of the 
adenosine system in Alzheimer’s disease. The beneficial effects of caffeine – a non-selective adenosine 
receptor  antagonist  –  and  of  specific  A2A  receptor  antagonists  are  discussed.  Rebecca  Williams-
Karnesky and Mary Stenzel-Poore highlight the role of adenosine as endogenous neuroprotectant of the 
brain  within  the  context  of  stroke.  Reprogramming  of  the  brain  and immune  responses  to  adenosine 
signaling  may  be  an  underlying  principle  of  tolerance  to  cerebral  ischemia.    Insight  into  the  role  of 
adenosine in various preconditioning paradigms may afford insight into new uses for adenosine as both an 
acute and prophylactic neuroprotectant. Theresa Lusardi discusses current knowledge about the role of 
adenosinergic  signalling  in  traumatic  brain  injury  (TBI).  In  the  central  nervous  system,  adenosine 
(dys)regulation  has  been  demonstrated  following  TBI,  and  correlated  to  several  TBI  pathologies, 
including impaired cerebral hemodynamics, anaerobic metabolism, and inflammation. In addition to acute 
pathologies, adenosine function has been implicated in TBI comorbidities, such as cognitive deficits, 
psychiatric function, and post-traumatic epilepsy. Theresa Bjornes and Robert Greene discuss the role 
of adenosine in sleep with a focus on slow wave sleep. This review highlights how adenosine influences 
sleep, and how sleep influences the adenosine system. New molecular data give a wealth of information, 
which receptors and mechanisms contribute to sleep control. Srdjan Vlajkovic, Gary Housley, and Peter 
Thorne present new insights how the adenosine system is involved in the regulation and maintenance of 
auditory functions. An interest in a potential otoprotective role for adenosine has recently evolved, fuelled 
by  the  capacity  of  A1  adenosine  receptors  to  prevent  cochlear  injury  caused  by  acoustic  trauma  and Release of Adenosine and ATP During Ischemia and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    159 
ototoxic drugs. The balance between A1 and A2A receptors is conceived as critical for cochlear response to 
oxidative stress, which is an underlying mechanism of the most common inner ear pathologies. Novel 
therapeutic targets and  strategies that  are based  on modulation of adenosine  signalling are presented. 
Finally, Susan Masino and colleagues discuss the potential of a ketogenic diet to raise brain levels of 
adenosine with a focus on exploiting the therapeutic potential of adenosine augmentation in epilepsy. As a 
closing statement for this special issue she presents the rationale how a ketogenic diet – or adenosine 
augmentation in general – could be of therapeutic benefit for brain injury, inflammatory and neuropathic 
pain, autism, and hyperdopaminergic disorders.   
  This Hot Topics Issue is expected to provide an overview on the rapidly emerging field of adenosine 
function  and  dysfunction  in  neurological  and  neuropsychiatric  conditions  with  a  focus  on  molecular 
mechanisms and possible therapeutic interventions. It can be expected that adenosine-based therapeutics 
for a wide variety of disorders will further be developed and refined during the next decade. This Hot 
Topics Issue shall provide an impetus for further research in this emerging area. 
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